▟ Vinebot intrinsic value, daily

← back

DVA DaVita

healthcare · valued with opus medium conviction · deep-dived 2026-10-21

STRONG BUY
Intrinsic value$149.96
Price (at call)$175.35
Margin of safety -14.5%
vs market (rating basis) +47.0%

A mature, levered dialysis duopolist whose pricing power and buybacks outrun stagnant volumes; modestly undervalued.

The story

DaVita is the #2 US dialysis provider in a two-player market alongside Fresenius. Its moat comes from scale, clinic density, and payer contracting leverage. The business is mature: patient volumes are flat to slightly down, and growth comes from rate increases, integrated kidney care, and modest international expansion. Commercial payers subsidize a Medicare book that barely breaks even, and heavy debt-funded buybacks (with Berkshire as anchor holder) amplify per-share results.

Growth of about 4.5% is mostly pricing and mix, since treatment volumes are stagnant, so it fades to 2.5% terminal, below the risk-free rate. Margin holds near the 14% TTM level rather than the 15.6% peak, because labor costs and Medicare Advantage rate pressure cap expansion. Beta sits above the 0.9 industry anchor to reflect net debt of about $9.6B against an $11B equity cap, and the 3% failure probability covers that leverage plus reimbursement policy risk.

Value drivers

Revenue growth (Y1)4.5%
Terminal growth2.5%
Forecast horizon6y
Target operating margin14.0%
Years to target margin3
Sales-to-capital1.40
Beta1.05
Failure probability3.0%
Cost of capital (WACC)8.5%
Terminal WACC8.3%

Valuation bridge

PV of explicit FCFF6.12B
PV of terminal value16.58B
Equity value9.57B
÷ shares → per share$149.96

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 14.46B 4.5% 14.3% 1.61B 444.70M 1.17B 1.08B
2 15.05B 4.1% 14.1% 1.66B 423.40M 1.24B 1.05B
3 15.61B 3.7% 14.0% 1.71B 397.76M 1.31B 1.03B
4 16.12B 3.3% 14.0% 1.77B 367.89M 1.40B 1.01B
5 16.59B 2.9% 14.0% 1.82B 333.96M 1.48B 988.30M
6 17.00B 2.5% 14.0% 1.86B 296.25M 1.57B 962.31M

Key risks

  • GLP-1s and SGLT2 drugs slow CKD progression, shrinking the dialysis patient census
  • Commercial payer mix erodes or Medicare/MA rates lag wage inflation, compressing the subsidy that funds profits
  • Leverage near 3.5x EBITDA leaves little cushion if a policy shock or cyber event (as in 2025) hits cash flow

Catalysts

  • Continued aggressive buybacks retiring 8-10% of shares annually at a discount to intrinsic value
  • Treatment volume stabilization plus integrated kidney care and international profitability improving the growth mix

History

DatePriceIntrinsicMoSRating
2026-10-21$175.35 $149.96 -14.5% STRONG BUY
2026-09-01$176.01 $263.41 +49.7% STRONG BUY
2026-07-10$229.48 $206.22 -10.1% STRONG BUY
2026-06-23$210.93 $183.22 -13.1% STRONG BUY